StockData
Savara Inc logo

Savara Inc (SVRA) stock

SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$4.48+0.02 (+0.34%)

Close on Nov 17, 2026Market cap $920.46MP/E –Yield –

Savara total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Savara's total debt was $30.11M at Jun 30, 2026. For fiscal 2025 it was $29.91M, up 12.4% from the year before. The highest annual figure on record is $29.91M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$29.91M+12.4%
FY2024Dec 31, 2024$26.62M+1.0%
FY2023Dec 31, 2023$26.35M+1.0%
FY2022Dec 31, 2022$26.08M+1.6%
FY2021Dec 31, 2021$25.66M+2.2%
FY2020Dec 31, 2020$25.10M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$30.11M+1.5%
Q1 FY2026Mar 31, 2026$30.07M+1.8%
Q4 FY2025Dec 31, 2025$29.91M+12.4%
Q3 FY2025Sep 30, 2025$29.78M+12.2%
Q2 FY2025Jun 30, 2025$29.65M+12.0%
Q1 FY2025Mar 31, 2025$29.52M+11.8%
Q4 FY2024Dec 31, 2024$26.62M+1.0%
Q3 FY2024Sep 30, 2024$26.55M+1.0%
Q2 FY2024Jun 30, 2024$26.48M+1.0%
Q1 FY2024Mar 31, 2024$26.42M+1.0%
Q4 FY2023Dec 31, 2023$26.35M+1.0%
Q3 FY2023Sep 30, 2023$26.28M+1.0%
Q2 FY2023Jun 30, 2023$26.21M+1.0%
Q1 FY2023Mar 31, 2023$26.15M+1.3%
Q4 FY2022Dec 31, 2022$26.08M+1.6%
Q3 FY2022Sep 30, 2022$26.01M+1.9%
Q2 FY2022Jun 30, 2022$25.94M+2.2%
Q1 FY2022Mar 31, 2022$25.81M+2.2%
Q4 FY2021Dec 31, 2021$25.66M+2.2%
Q3 FY2021Sep 30, 2021$25.52M–
Q2 FY2021Jun 30, 2021$25.38M–
Q1 FY2021Mar 31, 2021$25.24M–
Q4 FY2020Dec 31, 2020$25.10M–

More Savara figures

See a number that looks wrong?